Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
2024

Correction on Biomarkers of Response to Ocrelizumab in Multiple Sclerosis

Editorial

Author Information

Author(s): Rodríguez-Jorge Fernando, Fernández-Velasco José Ignacio, Villarrubia Noelia, Gracia-Gil Julia, Fernández Eva, Meca-Lallana Virginia, Díaz-Pérez Carolina, Sainz de la Maza Susana, Pacheco Eva María, Quiroga Ana, Ramió-Torrentà Lluis, Martínez-Yélamos Sergio, Bau Laura, Monreal Enric, López-Real Ana, Rodero-Romero Alexander, Borrega Laura, Díaz Santiago, Eguía Pablo, Espiño Mercedes, Chico-García Juan Luis, Barrero Francisco Javier, Martínez-Ginés María Luisa, García-Domínguez José Manuel, De la Fuente Soraya, Moreno Irene, Sainz-Amo Raquel, Mañé-Martínez M. Alba, Caminero Ana, Castellanos-Pinedo Fernando, Gómez López Ana, Labiano-Fontcuberta Andrés, Ayuso Lucía, Abreu Rossana, Hernández Miguel Ángel, Meca-Lallana José, Martín-Aguilar Lorena, Muriel García Alfonso, Masjuan Jaime, Costa-Frossard Lucienne, Villar Luisa María

Primary Institution: Hospital Universitario Ramón y Cajal, Madrid, Spain

Conclusion

The correction does not change the scientific conclusions of the original article.

Takeaway

The authors fixed a name error in their article, but it doesn't affect the study's findings.

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1535051

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication